23Andme Holding Co Stock Price, News & Analysis

23andMe Holding Co. (Nasdaq: ME) announced the redemption of all outstanding Public and Private Warrants to purchase shares of its Class A common stock. The redemption price is set at $0.10 per Warrant, effective by 5:00 p.m. NYC time on December 22, 2021. The redemption is triggered if the Class A common stock's Reference Value equals or exceeds $10.00 per share for twenty trading days within a thirty-day trading period. Holders may exercise their Warrants until the Redemption Date, after which unexercised Warrants will become void.

23andMe Holding Co. (Nasdaq: ME) reported a Q2 FY2022 revenue of $55 million, a 7% increase year-over-year. The company completed the acquisition of Lemonaid Health, enhancing its telemedicine offerings. The consumer services segment accounted for 81% of total revenue. Operating expenses rose to $74 million due to R&D and marketing investments. The net loss improved to $17 million from $36 million in the prior year, driven by favorable changes in warrant liabilities. Cash reserves increased to $701 million following a prior business combination.

23andMe Holding Co. (Nasdaq: ME) announced its participation in three upcoming virtual investor conferences scheduled for November and December 2021. The conferences include:

• Credit Suisse 30th Annual Healthcare Conference on November 11 at 12:10 pm ET
• Piper Sandler 33rd Annual Healthcare Conference with a pre-recorded chat available the week of November 22
• Evercore ISI 4th Annual HealthCONx Conference on December 2 at 2:15 pm ET

Webcasts of these presentations will be accessible on the company's investor website.

23andMe Holding Co. (Nasdaq: ME) announced the appointment of Dr. Sandra Hernández to its Board of Directors. Dr. Hernández, currently the President & CEO of the California Health Care Foundation, brings a wealth of experience in improving healthcare access, particularly for underserved communities. Her leadership is expected to enhance 23andMe’s efforts in delivering personalized healthcare experiences. Anne Wojcicki, CEO of 23andMe, emphasized Dr. Hernández’s expertise as vital for the company’s mission of providing affordable and accessible care.

23andMe Holding Co. (Nasdaq: ME) will report its financial results for the fiscal year 2022 second quarter on November 10, 2021, after market close. A conference call is scheduled for 4:30 p.m. Eastern Time. Shareholders can submit questions via the Say Technologies platform ahead of the earnings call. 23andMe has established itself as a leader in consumer genetics, with multiple FDA authorizations for health risk reports and a robust research platform that has facilitated over 180 publications on genetic diseases.

23andMe Holding Co. (Nasdaq: ME) has acquired Lemonaid Health, a telemedicine platform, enhancing its consumer healthcare offerings. This acquisition aims to provide personalized healthcare, leveraging genetics as a foundation. Lemonaid's services will integrate into 23andMe’s consumer business, led by its co-founder Paul Johnson as Vice President. The deal emphasizes better access to affordable healthcare and aligns with 23andMe's mission of empowering individuals through genetic information.

23andMe Holding Co. (Nasdaq: ME) has signed a definitive merger agreement to acquire Lemonaid Health, Inc. for approximately $400 million, with 25% in cash and 75% in shares. This acquisition aims to enhance 23andMe's telemedicine capabilities, allowing for personalized healthcare through a combination of genetics and telemedicine services. The deal is anticipated to close by the end of 2021, with Lemonaid’s CEO, Paul Johnson, transitioning to lead 23andMe's consumer business.

23andMe Holding Co. (Nasdaq: ME) will report its fiscal year 2022 second-quarter financial results before the market opens on November 10, 2021. A conference call will be held at 4:30 p.m. ET to discuss these results alongside business progress. 23andMe is noted for its pioneering role in consumer genetics and has multiple FDA authorizations for genetic health risk reports. The company has built the world's largest crowdsourced platform for genetic research, contributing to over 180 publications in genetic studies.

23andMe Holding Co. (Nasdaq: ME) announced its participation in the Wells Fargo Virtual Healthcare Conference on September 10, 2021, at 8:20 a.m. PT. Investors can access the live webcast on the company's website. The session will provide updates on the company's developments in consumer genetics and therapeutics. Founded in 2006, 23andMe aims to enhance public access to genetic information and has the world's largest crowdsourced genetic research platform.